Bioresorbable Vascular Scaffolds for Percutaneous Treatment of Chronic Total Coronary Occlusions: a Meta-analysis

Overview

Journal BMC Cardiovasc Disord

Publisher Biomed Central

Specialty Cardiology & Vascular Diseases

Date 2019 Mar 17

PMID 30876408

Citations 3

Authors

Alberto Polimeni

Remzi Anadol

Thomas Munzel

Martin Geyer

Salvatore De Rosa

Ciro Indolfi

Tommaso Gori

Affiliations

Soon will be listed here.

Abstract

Background: BRS represent a new approach to treating coronary artery disease. Beneficial properties of BRS regarding the restoration of vasomotility after resorption make them attractive devices in CTO revascularization. However, experience in this setting is limited.

Methods: We systematically searched Medline, Scholar, and Scopus for reports of at least 9 patients with CTO undergoing BRS implantation. Patients' and procedural characteristics were summarized. The primary outcome of interest was target lesion revascularization (TLR). Pooled estimates were calculated using a random-effects meta-analysis. The study protocol was registered in PROSPERO (CRD42017069322).

Results: Thirteen reports for a total of 843 lesions with a median follow-up of 12 months (IQR 6-12) were included in the analysis. At short-term, the summary estimate rate of TLR was 2.6% (95% CI: 1 to 4%, I = 0%, P = 0.887) while at mid to long-term it was 3.8% (95% CI: 2 to 6%, I = 0%, P = 0.803). At long-term follow-up (≥12 months), the summary estimate rate of cardiac death was 1.1% (95% CI: 0 to 2%, I = 0%, P = 0.887). The summary estimate rates of scaffold thrombosis and clinical restenosis were respectively 0.9% (95% CI: 0 to 2%, I = 0%, P = 0.919) and 1.8% (95% CI: 0 to 4%, I = 0%, P = 0.448). Finally, the summary estimate rate of target vessel revascularization was 6.6% (95% CI: 0 to 11%, I = 0%, P = 0.04).

Conclusions: Implantation of BRS in a population with CTO is feasible, although further longer-term outcome studies are necessary.

Citing Articles

Stent Thrombosis and Restenosis with Contemporary Drug-Eluting Stents: Predictors and Current Evidence.

Condello F, Spaccarotella C, Sorrentino S, Indolfi C, Stefanini G, Polimeni A J Clin Med. 2023; 12(3).

PMID: 36769886 PMC: 9917386. DOI: 10.3390/jcm12031238.

Bioresorbable Vascular Scaffolds-Dead End or Still a Rough Diamond?.

Jezewski M, Kubisa M, Eyileten C, De Rosa S, Christ G, Lesiak M J Clin Med. 2019; 8(12).

PMID: 31817876 PMC: 6947479. DOI: 10.3390/jcm8122167.

Hybrid Coronary Percutaneous Treatment with Metallic Stents and Everolimus-Eluting Bioresorbable Vascular Scaffolds: 2-years Results from the GABI-R Registry.

Gori T, Achenbach S, Riemer T, Mehilli J, Nef H, Naber C J Clin Med. 2019; 8(6).

PMID: 31151213 PMC: 6617525. DOI: 10.3390/jcm8060767.

References

Stone G, Gao R, Kimura T, Kereiakes D, Ellis S, Onuma Y . 1-year outcomes with the Absorb bioresorbable scaffold in patients with coronary artery disease: a patient-level, pooled meta-analysis. Lancet. 2016; 387(10025):1277-89. DOI: 10.1016/S0140-6736(15)01039-9. View

Brugaletta S, Gomez-Lara J, Caballero J, Ortega-Paz L, Teruel L, Fernandez M . Ticagrelor versus clopidogrel for recovery of vascular function immediately after successful chronic coronary total occlusion recanalization: A randomized clinical trial. Am Heart J. 2018; 204:205-209. DOI: 10.1016/j.ahj.2018.07.013. View

Colmenarez H, Escaned J, Fernandez C, Lobo L, Cano S, del Angel J . Efficacy and safety of drug-eluting stents in chronic total coronary occlusion recanalization: a systematic review and meta-analysis. J Am Coll Cardiol. 2010; 55(17):1854-66. DOI: 10.1016/j.jacc.2009.12.038. View

Mitomo S, Naganuma T, Fujino Y, Kawamoto H, Basavarajaiah S, Pitt M . Bioresorbable Vascular Scaffolds for the Treatment of Chronic Total Occlusions: An International Multicenter Registry. Circ Cardiovasc Interv. 2017; 10(1). DOI: 10.1161/CIRCINTERVENTIONS.116.004265. View

Wallace B, Dahabreh I, Schmid C, Lau J, Trikalinos T . Modernizing the systematic review process to inform comparative effectiveness: tools and methods. J Comp Eff Res. 2013; 2(3):273-82. DOI: 10.2217/cer.13.17. View

Goktekin O, Yamac A, Latib A, Tastan A, Panoulas V, Sato K . Evaluation of the Safety of Everolimus-Eluting Bioresorbable Vascular Scaffold (BVS) Implantation in Patients With Chronic Total Coronary Occlusions: Acute Procedural and Short-Term Clinical Results. J Invasive Cardiol. 2015; 27(10):461-6. View

Saad M, Abdin A, Thiele H, Desch S, Ibrahimi P, Wikstroem G . Bioresorbable Vascular Scaffolds in a Real-World Patient Population-Results From a Mid-Term Angiographic Follow-Up. J Interv Cardiol. 2016; 29(4):341-7. DOI: 10.1111/joic.12297. View

Ozel E, Tastan A, Ozturk A, Ozcan E, Kilicaslan B, Ozdogan O . Procedural and one-year clinical outcomes of bioresorbable vascular scaffolds for the treatment of chronic total occlusions: a single-centre experience. Cardiovasc J Afr. 2016; 27(6):345-349. PMC: 5408394. DOI: 10.5830/CVJA-2016-033. View

Azzalini L, Giustino G, Ojeda S, Serra A, La Manna A, Ly H . Procedural and Long-Term Outcomes of Bioresorbable Scaffolds Versus Drug-Eluting Stents in Chronic Total Occlusions: The BONITO Registry (Bioresorbable Scaffolds Versus Drug-Eluting Stents in Chronic Total Occlusions). Circ Cardiovasc Interv. 2016; 9(10). DOI: 10.1161/CIRCINTERVENTIONS.116.004284. View

10.

Fam J, Ojeda S, Garbo R, Latib A, La Manna A, Vaquerizo B . Everolimus-eluting bioresorbable vascular scaffolds for treatment of complex chronic total occlusions. EuroIntervention. 2017; 13(3):355-363. DOI: 10.4244/EIJ-D-16-00253. View

11.

Biscaglia S, Ugo F, Ielasi A, Secco G, Durante A, DAscenzo F . Bioresorbable Scaffold vs. Second Generation Drug Eluting Stent in Long Coronary Lesions requiring Overlap: A Propensity-Matched Comparison (the UNDERDOGS study). Int J Cardiol. 2016; 208:40-5. DOI: 10.1016/j.ijcard.2016.01.202. View

12.

Vaquerizo B, Barros A, Pujadas S, Bajo E, Jimenez M, Gomez-Lara J . One-Year Results of Bioresorbable Vascular Scaffolds for Coronary Chronic Total Occlusions. Am J Cardiol. 2016; 117(6):906-17. DOI: 10.1016/j.amjcard.2015.12.025. View

13.

Kugler C, Markovic S, Rottbauer W, Wohrle J . Bioresorbable scaffolds compared with everolimus-eluting stents for the treatment of chronic coronary total occlusion: clinical and angiographic results of a matched paired comparison. Coron Artery Dis. 2016; 28(2):120-125. DOI: 10.1097/MCA.0000000000000449. View

14.

Anadol R, Dimitriadis Z, Polimeni A, Wendling F, Gonner S, Ullrich H . Bioresorbable everolimus-eluting vascular scaffold for patients presenting with non STelevation-acute coronary syndrome: A three-years follow-up1. Clin Hemorheol Microcirc. 2018; 69(1-2):3-8. DOI: 10.3233/CH-189101. View

15.

Polimeni A, Anadol R, Munzel T, Indolfi C, De Rosa S, Gori T . Long-term outcome of bioresorbable vascular scaffolds for the treatment of coronary artery disease: a meta-analysis of RCTs. BMC Cardiovasc Disord. 2017; 17(1):147. PMC: 5463321. DOI: 10.1186/s12872-017-0586-2. View

16.

Jones D, Weerackody R, Rathod K, Behar J, Gallagher S, Knight C . Successful recanalization of chronic total occlusions is associated with improved long-term survival. JACC Cardiovasc Interv. 2012; 5(4):380-8. DOI: 10.1016/j.jcin.2012.01.012. View

17.

Sorrentino S, Giustino G, Mehran R, Kini A, Sharma S, Faggioni M . Everolimus-Eluting Bioresorbable Scaffolds Versus Everolimus-Eluting Metallic Stents. J Am Coll Cardiol. 2017; 69(25):3055-3066. DOI: 10.1016/j.jacc.2017.04.011. View

18.

Yang S, Tang L, Ge G, Li R, Qu X, Fang W . Efficacy of drug-eluting stent for chronic total coronary occlusions at different follow-up duration: a systematic review and meta-analysis. Eur Rev Med Pharmacol Sci. 2015; 19(6):1101-16. View

19.

Indolfi C, De Rosa S, Colombo A . Bioresorbable vascular scaffolds - basic concepts and clinical outcome. Nat Rev Cardiol. 2016; 13(12):719-729. DOI: 10.1038/nrcardio.2016.151. View

20.

Yamac A, Yildiz A, Nasifov M, Tastan A, Bashirov N, Goktekin O . Clinical and angiographic outcomes at more than 1 year after treatment of chronic total occlusions with the everolimus-eluting bioresorbable vascular scaffold. Turk Kardiyol Dern Ars. 2017; 44(8):647-655. DOI: 10.5543/tkda.2016.21774. View